FRIDAY, Sept. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering the United States.
TUESDAY, Sept. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase.
FRIDAY, Aug. 29, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is now providing real-time, daily publication updates on adverse event data from its reporting system.
GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals are ahead.
WEDNESDAY, June 18, 2025 (HealthDay News) -- On Tuesday, the U.S. Food and Drug Administration announced a new initiative to offer expedited reviews for new medicines, an initiative that will apply to drugs that administration officials determine promote "the health interests of Americans."
TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.
